A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
- Resource Type
- Journal
- Source
CLINICAL CANCER RESEARCH ; APR 15 2017, 23 8, p1910-p1919, 10p.- Subject
- Language
- English
- ISSN
- 15573265